Special Issue "Drug-Repositioning Opportunities for Antiviral Therapy"
Deadline for manuscript submissions: closed (20 December 2020).
With the emergence of Covid-19 in China, it is clear that viral infections have a high risk of causing public health crisis. This novel coronavirus has created awareness that the appearance of new transmissible viruses is a global risk with an enormous social, health, and economic impact.
Several viruses, such as Ebola virus, MERS-CoV, Nipah virus, and COVID-19, among other, are recognized as emerging viruses of global threat and as top priorities requiring the development of strategies for prevention and treatment. On the other hand, several familiar viruses continue to cause significant morbidity and mortality, as exemplified by human cytomegalovirus in immunocompromised hosts and in neonates.
There is a continuing and growing need to develop new antiviral strategies that result in increased selectivity (i.e., lower toxicity and greater activity) and higher drug-resistance barriers to manage viral infections. Although significant efforts have been done leading to the approval of about 30 antivirals, the identification of druggable targets, the development of direct acting antivirals (DAA) and host-directed antiviral (HDA) candidates, and repurposed drugs remain a priority.
In this Special issue, a special emphasis will be given to the investigation of drug repurposing as a novel antiviral strategy to combat emerging and re-emerging viral diseases. Drug repurposing, also known as redirecting, repurposing, repositioning, and re-profiling, is an alternative to the classical process of development of antivirals. Drug repurposing, the process of identifying new uses for existing or candidate drugs, is a fast and cost-effective method that can overcome traditional de novo drug discovery. This process can be very useful in emergencies, such as the one currently caused by Covid-19. The drug repurposing approach has identified some promising drug candidates for different viral diseases like Ebola, ZIKA, dengue, influenza, HIV, herpes simplex virus (HSV), CMV, and Covid-19 infections.
This Special issue aims to explore drug repurposing as an approach to find candidate antiviral agents within a short span of time to overcome the challenges of drug development and the global threat of emerging and re-emerging viral infectious diseases. We welcome original research and comprehensive review articles presenting recent progress, challenges, and future perspectives of drug repurposing in antiviral drug discovery.
Prof. Dr. Graciela Andrei
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Drug repurposing
- Emerging and re-emerging viral diseases
- Antiviral strategies
- Antiviral drug discovery
- Druggable antiviral targets
- Direct acting antivirals
- Host-directed antivirals
- Drug-resistant viruses